TY  - GEN
AU  - Meraviglia,S
AU  - Eberl,M
AU  - Vermijlen,D
AU  - Todaro,M
AU  - Buccheri,S
AU  - Cicero,G
AU  - La Mendola,C
AU  - Guggino,G
AU  - D'Asaro,M
AU  - Orlando,V
AU  - Scarpa,F
AU  - Roberts,A
AU  - Caccamo,N
AU  - Stassi,G
AU  - Dieli,F
AU  - Hayday,A C
TI  - In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients
SN  - 1365-2249
PY  - 2010///0827
KW  - Adjuvants, Immunologic
KW  - adverse effects
KW  - Aged
KW  - Breast Neoplasms
KW  - blood
KW  - Cell Proliferation
KW  - drug effects
KW  - Chemokines
KW  - Cytokines
KW  - Diphosphonates
KW  - Disease Progression
KW  - Esterases
KW  - metabolism
KW  - Female
KW  - Hemiterpenes
KW  - pharmacology
KW  - Humans
KW  - Imidazoles
KW  - Immunotherapy
KW  - methods
KW  - Interferon-gamma
KW  - Interleukin-2
KW  - Leukocyte Common Antigens
KW  - Lymphocyte Activation
KW  - Lymphocyte Count
KW  - Lysine
KW  - analogs & derivatives
KW  - Middle Aged
KW  - Mucin-1
KW  - Organophosphorus Compounds
KW  - Receptors, Antigen, T-Cell, gamma-delta
KW  - Remission Induction
KW  - Salvage Therapy
KW  - T-Lymphocyte Subsets
KW  - cytology
KW  - TNF-Related Apoptosis-Inducing Ligand
KW  - Treatment Outcome
KW  - Tumor Necrosis Factor Receptor Superfamily, Member 7
KW  - Zoledronic Acid
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/j.1365-2249.2010.04167.x
ER  -